PTC Therapeutics,PTC Therapeutics, a biopharmaceutical company and development of small and development of small molecule drugs targeting post – transcriptional control processes, today announced with positive preliminary data from a Phase 2 clinical trial of PTC124 in patients Duchenne muscular dystrophy due to a nonsense mutation. The results from the first two cohorts of the three – cohort study show that treatment with PTC124 was associated with increases in muscle dystrophin expression and decrease in serum creatinine kinase levels in 50 % of evaluable patients.

The DOE JGI, already the most productive genome sequencing centers in the world with more than 225 organisms to its credit, is poised to this sum and the scientific literature through its Community Sequencing Program significantly.

About PTC124PTC124 is an orally delivered investigational new drug in Phase 2 clinical development for the treatment of genetic disorders due to nonsense mutations. Nonsense mutations are single-point alterations in the genetic code that prematurely the translation process the translation process, producing a shortened, non – functional protein. PTC124 restored production at full length, functional proteins in preclinical genetic disease models harboring nonsense mutations.The results fix new strategies for the prevention for prostate cancer recurrent or progression of following treatment, the drug therapies, lifestyle changes and involve both lead would, Freeman said.

Freeman team will be about 500 men the Chicago area health centers, examine clinically early -stage prostate cancer and the candidates for curative therapy to operation are.